Breyanzi

ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
Fierce Pharma
ASCO 2023
Bristol Myers Squibb
Breyanzi
CAR-T
CLL
SLL
clinical trials
Flag link:
Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Fierce Pharma
Bristol Myers Squibb
Breyanzi
Celgene
legal
M&A
CVRs
Flag link:
Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia
Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia
Endpoints
Bristol Myers Squibb
CAR-T
Breyanzi
CLL
cell therapy
Flag link:
ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead
ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead
Fierce Pharma
Bristol Myers Squibb
Breyanzi
B-cell lymphoma
CAR-T
ASH 2022
Flag link:
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
Fierce Pharma
Bristol Myers Squibb
generics
Revlimid
Abecma
Breyanzi
Pharma CEOs
Giovanni Caforio
Flag link:
Federal judge denies Bristol Myers' attempt to avoid Celgene shareholder lawsuit
Federal judge denies Bristol Myers' attempt to avoid Celgene shareholder lawsuit
Endpoints
Celgene
Bristol Myers Squibb
Breyanzi
legal
Flag link:
Amidst Legal Battle, BMS' CAR-T Therapy Scores Second FDA Approval
Amidst Legal Battle, BMS' CAR-T Therapy Scores Second FDA Approval
BioSpace
Bristol Myers Squibb
CAR-T
Breyanzi
liso-cel
FDA
large B-cell lymphoma
Flag link:
'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update
'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update
Fierce Pharma
Bristol Myers Squibb
legal
Breyanzi
shareholders
CAR-T
liso-cel
lymphoma
Flag link:
Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms
Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms
Fierce Pharma
Bristol Myers Squibb
CAR-T
Breyanzi
Abecma
Flag link:
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
Flag link:
ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma
ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma
Fierce Pharma
Gilead Sciences
Yescarta
Bristol Myers Squibb
Breyanzi
CAR-T
lymphoma
Flag link:
BMS will file for earlier-line use of Breyanzi in lymphoma after trial win
BMS will file for earlier-line use of Breyanzi in lymphoma after trial win
Pharmaforum
Bristol Myers Squibb
CAR-T
Breyanzi
large B-cell lymphoma
Novartis
Gilead Sciences
FDA
Flag link:
Bristol Myers' CAR-T Breyanzi busts out a win in earlier-line lymphoma, potentially cracking open an expanded market
Bristol Myers' CAR-T Breyanzi busts out a win in earlier-line lymphoma, potentially cracking open an expanded market
Endpoints
Bristol-Myers Squibb
CAR-T
Breyanzi
B cell lymphoma
Flag link:
Bristol-Myers is sued for $6.4 billion over delayed cancer drug
Bristol-Myers is sued for $6.4 billion over delayed cancer drug
Reuters
Bristol Myers Squibb
Breyanzi
legal
Celgene
Flag link:
Bristol Myers sees automation, virtual reality on the horizon for pair of new CAR-T manufacturing plants
Bristol Myers sees automation, virtual reality on the horizon for pair of new CAR-T manufacturing plants
Fierce Pharma
Bristol Myers Squibb
CAR-T
drug manufacturing
Breyanzi
Abecma
Flag link:
Bristol Myers, with Breyanzi nod in hand, eyes faster cell therapy production
Bristol Myers, with Breyanzi nod in hand, eyes faster cell therapy production
Fierce Pharma
Bristol-Myers Squibb
cell therapy
Breyanzi
drug manufacturing
Flag link:
Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi
Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi
Fierce Pharma
Bristol Myers Squibb
Breyanzi
CAR-T
lymphoma
Novartis
Kymriah
Flag link: